ATF3 repression of BCL-X(L) determines apoptotic sensitivity to HDAC inhibitors across tumour types

PURPOSE: Histone deacetylase inhibitors (HDACi) are epigenome-targeting small molecules approved for the treatment of cutaneous T cell lymphoma and multiple myeloma. They have also demonstrated clinical activity in AML, non-small cell lung cancer and estrogen receptor-positive breast cancer, and tri...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Chueh, Anderly C., Tse, Janson WT, Dickinson, Michael, Ioannidis, Paul, Jenkins, Laura, Togel, Lars, Tan, BeeShin, Luk, Ian, Davalos-Salas, Mercedes, Nightingale, Rebecca, Thompson, Matthew R., Williams, Bryan R.G., Lessene, Guillaume, Lee, Erinna, Fairlie, Walter D., Dhillon, Amardeep S., Mariadason, John M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5600837/
https://ncbi.nlm.nih.gov/pubmed/28611196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0466
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados